News

  • 13 June 2012

    Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that KUR-023, its novel dural sealant product candidate, successfully sealed intra-operative CSF leakage in all evaluable patients.

  • 12 June 2012

    Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its TactiCath Quartz force-sensing ablation catheter has been CE mark approved. In cooperation with the company’s distributor BIOTRONIK, first cases using the new device have been performed by renowned physicians at three centers across Europe: Dr. Dipen Shah from University Hospital of Geneva; Dr. Georg Nölker from Heart and Diabetes Center in Bad Oeynhausen, Germany; and, Dr. Reza Wakili and Dr. Heidi Estner from University Hospital Grosshadern in Munich.

  • 12 June 2012

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the closing of its acquisition of EUSA Pharma, a privately-held, specialty pharmaceutical company with a commercial presence in the U.S. and EU and a global distribution network. The acquisition brings a significant new specialty product to the company's U.S. product portfolio with Erwinaze™ (asparaginase Erwinia chrysanthemi), a life-saving treatment for patients with acute lymphoblastic leukemia.  Following the closing, Jazz Pharmaceuticals now also markets a portfolio of oncology and critical care products outside of the U.S., including Erwinase®, leveraging EUSA Pharma's international sales and marketing capabilities.

  • 21 May 2012

    Zürich-based company Sequana Medical reported that Switzerland’s first patients have received the ALFApump® System. The ALFApump® System is a fully implantable pump system designed to remove excess abdominal fluid, known as ascites, that collects in patients suffering from advanced chronic liver disease.

  • 1 May 2012

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformité Européenne (CE) Mark approval for its V2 Renal Denervation System™ for the treatment of hypertension. Renal denervation is a percutaneous, catheter-based therapy that uses RF energy to disrupt renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.